St George's University Hospitals NHS Foundation Trust, London, UK.
Dutch Association for People with Atopic Dermatitis, Nijkerk, Netherlands.
Clin Exp Dermatol. 2021 Mar;46(2):259-269. doi: 10.1111/ced.14473. Epub 2020 Oct 27.
This narrative review highlights the therapeutic significance of topical corticosteroid (TCS) vehicles and provides subsequent guidance to improve clinical and research outcomes. A greater understanding of the relationship between the topical vehicle, corticosteroid and skin is needed to ensure safer, more effective treatment for patients. Topical vehicles are not inert and can affect TCS bioavailability, due to the ability of their composition to positively or negatively influence skin status and change the physiochemical characteristics of an inherent corticosteroid. However, this principle is not commonly understood, and has contributed to inconsistencies in potency classification systems. This review provides an insight into the research methods and standardization needed to determine TCS product bioavailability. It identifies formulation components responsible for vehicle composition that underpin the quality, stability, compounding and functionalities of vehicle ingredients. This helps to contextualize how topical vehicles can be responsible for clinically significant effects, and how their composition gives products unique properties. In turn, this facilitates a more in-depth understanding of which resources offer information to inform the best selection of TCS products and why products should be prescribed by brand or manufacturer. This review will better equip clinicians and formulary teams to appraise products. It will also inform prescribing of Specials and why products should not be manipulated. The recommendations, accompanied by patient perspectives on using TCS products, assist clinical decision-making. They also identify the need for research into concomitant application of TCS products with other topical therapies.
这篇叙述性综述强调了局部皮质类固醇(TCS)制剂的治疗意义,并为改善临床和研究结果提供了后续指导。为了确保患者得到更安全、更有效的治疗,需要加深对局部制剂、皮质类固醇和皮肤之间关系的理解。局部制剂并非惰性物质,由于其成分具有积极或消极影响皮肤状态并改变固有皮质类固醇的物理化学特性的能力,它们会影响 TCS 的生物利用度。然而,这一原则尚未被广泛理解,这导致了效力分类系统的不一致。这篇综述深入探讨了确定 TCS 产品生物利用度所需的研究方法和标准化。它确定了负责制剂组成的配方成分,这些成分是制剂质量、稳定性、配制和功能的基础。这有助于了解局部制剂如何能够产生临床显著的效果,以及它们的组成如何赋予产品独特的特性。反过来,这有助于更深入地了解哪些资源提供了信息,以便为 TCS 产品的最佳选择提供信息,以及为什么应该根据品牌或制造商来开处方。这篇综述将使临床医生和处方团队更好地评估产品。它还将告知特殊药物的开处方问题,以及为什么不应操纵产品。这些建议结合了患者对使用 TCS 产品的看法,有助于临床决策。它们还确定了研究 TCS 产品与其他局部治疗同时应用的必要性。